Nucleus Bets Alliances Beat Building It All in House

A Rochester CDMO adds Thermo Fisher's analytical muscle to its radiopharmaceutical development stack.

18 Jun 2026

Nucleus RadioPharma has struck a strategic alliance with Thermo Fisher Scientific to sharpen radiopharmaceutical development and clinical execution. The Rochester, Minnesota based contract development and manufacturing organization builds clinical and commercial supply chains for targeted radiotherapies. Thermo Fisher's scale and analytical expertise now slots directly into that effort.

This is not an isolated move. Earlier the same month, Nucleus signed a master purchase and supply agreement with BWXT Medical covering critical radiopharmaceutical isotopes. Stack the two deals together and a pattern emerges: a company methodically closing the infrastructure gaps that have slowed radiopharmaceutical programs from reaching patients.

For sponsors juggling alpha and beta emitting radiotherapeutics, the alliance offers a shortcut. Building every capability in house is expensive and slow. Thermo Fisher's instrumentation and development expertise can compress timelines for radiochemistry and quality testing, the exact bottlenecks that have tripped up smaller biotech sponsors pushing candidates from preclinical work toward commercial supply.

Nucleus already runs a fully operational Rochester facility, with an expansion site under construction in Pennsylvania, giving it dedicated capacity for actinium-225, lutetium-177, lead-212 and copper-67. As sponsors increasingly hunt for CDMO partners offering both isotope flexibility and downstream development support, alliances like this one are becoming table stakes rather than a nice-to-have.